Influenza Cases Surge, Kimia Farma (KAEF) Develops This Anti-Virus
State-owned pharmaceutical issuer, PT Kimia Farma (Persero) Tbk (KAEF), has signed a sub-licence agreement with the Medicines Patent Pool (MPP). This agreement grants Kimia Farma the rights to develop and produce a generic version of Baloxavir marboxil, an innovative anti-viral drug for the treatment of influenza developed by the global pharmaceutical company, Roche.
The announcement regarding the sub-licence was made by the MPP on 25 September 2026 through its official channel during the United Nations General Assembly (UNGA) in New York. Through this voluntary licence, Kimia Farma has been selected as the sole manufacturer from Indonesia among 11 manufacturing companies worldwide.
Kimia Farma joins a group of leading regional and global producers from countries including Brazil, China, India, Malaysia, Nigeria, Uganda, Ukraine, and Vietnam.
The granting of this sub-licence provides Kimia Farma with full access to the technical data package, reference products for bioequivalence studies, and other technical support to accelerate the development, registration, and regulatory approval processes within the country.
By producing Baloxavir marboxil locally in Indonesia, Kimia Farma is playing an active role in strengthening the supply chain for essential medicines and reducing dependence on imported anti-viral drugs.
The Executive Director of the Medicines Patent Pool (MPP), Charles Gore, stated that this effort is a crucial step in building global health supply resilience before health emergencies occur. “By combining global manufacturing capacity and regional-based production, we are helping to build a more diverse and resilient supply base for the future,” he said, as quoted on Thursday (1/10/2026).
Meanwhile, the Commercial Director of PT Kimia Farma (Persero) Tbk, Hanadi Setiarto, said that the Company’s involvement in this global initiative is part of Kimia Farma’s commitment to continuously developing capabilities and increasing the competitiveness of the national pharmaceutical industry.
“Kimia Farma’s involvement in this sub-licence agreement is a strategic step to strengthen the capabilities of the national pharmaceutical industry while supporting Indonesia’s preparedness in facing various future health conditions. Through collaboration with global partners, we gain the opportunity to strengthen our abilities in development, regulation, and manufacturing, as well as to contribute to national health resilience,” said Hanadi.
Source: jawawa.id (https://jawawa.id/newsitem/influenza-cases-surge-kimia-farma-kaef-develops-this-anti-virus-1790834184)
Originally published by CNBC Indonesia (https://www.cnbcindonesia.com/market/20261001103721-17-772425/korban-influenza-meroket-kimia-farma--kaef--kembangkan-anti-virus-ini), translated from Indonesian